Groupe Bruxelles Lambert SA stock (BE0003797140): Solid start to 2026 with new private?asset deals and portfolio simplification

Groupe Bruxelles Lambert SA reports a strong start to 2026, posting value creation of €47 million and completing two new private?asset investments while simplifying its listed portfolio.

Groupe Bruxelles Lambert SA has reported a solid start to 2026, highlighting value creation of €47 million and two new private?asset investments as it continues to simplify its portfolio of listed holdings. The Brussels?based investment group published its results for the three months ended March 31, 2026 on May 7, 2026, underscoring progress toward its medium?term plan and a shift toward direct private?asset exposure.Zonebourse as of 07/05/2026

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Groupe Bruxelles Lambert SA
• Sector/industry: Investment holding / diversified investments
• Headquarters/country: Belgium
• Core markets: Europe, with global exposure via portfolio companies
• Key revenue drivers: Capital gains and dividends from listed and private holdings, including healthcare, technology and infrastructure
• Home exchange/listing venue: Euronext Brussels (ticker: GBL)
• Trading currency: EUR

Groupe Bruxelles Lambert SA: core business model

Groupe Bruxelles Lambert SA operates as an active, long?term investment holding company focused on creating value across a diversified portfolio of listed and private assets. The group targets sectors such as healthcare, technology, infrastructure and consumer?oriented businesses, often taking significant or controlling stakes and working closely with management teams to drive operational improvements and strategic growth.GBL Investors as of 09/05/2026

GBL’s strategy emphasizes active ownership, long?term value creation and disciplined capital allocation. The company regularly reviews its portfolio, trimming or exiting positions that no longer fit its strategic focus while reinvesting proceeds into higher?return opportunities, particularly in private assets where it can exert influence and capture illiquidity premiums.Zonebourse as of 07/05/2026

Main revenue and product drivers for Groupe Bruxelles Lambert SA

For the first quarter of 2026, GBL reported value creation of €47 million, driven by portfolio companies in healthcare such as Affidea and Sanoptis, which contributed to the group’s net asset value growth.Zonebourse as of 07/05/2026 The group also completed two new direct private?asset investments, including a majority stake in BUKO Group, a leading platform in temporary traffic management, for an equity outlay of about €0.5 billion, and a co?control investment in Rayner, a medtech platform in ophthalmic devices, also for around €0.5 billion in equity.Zonebourse as of 07/05/2026

At the same time, GBL continued to simplify its portfolio of listed holdings, reducing its stake in Concentrix from 14.4% to 4.5% on April 29, 2026, generating a net disposal proceeds of about €0.1 billion.Zonebourse as of 07/05/2026 Total disposal proceeds since the start of its medium?term plan reached about €4.9 billion, or roughly 97% of the target amount, reflecting a deliberate shift toward private assets and a leaner listed portfolio.Zonebourse as of 07/05/2026

GBL’s financial profile remains robust, with a liquidity buffer of about €6.2 billion and a net cash position of more than €1.2 billion, which the company says supports future investments and shareholder returns.Marketscreener as of 07/05/2026 The group’s net asset value per share rose from about €99.86 at the end of 2025 to around €111.17 at March 31, 2026, reflecting both capital gains and the impact of new investments.Marketscreener as of 07/05/2026

Conclusion

Groupe Bruxelles Lambert SA has delivered a solid start to 2026, combining value creation from existing holdings with two sizable private?asset investments and continued portfolio simplification. The group’s shift toward direct private?asset exposure and its strong liquidity position position it to pursue further targeted deals while maintaining flexibility for shareholder returns.Zonebourse as of 07/05/2026

For US investors, GBL offers exposure to a diversified European investment holding with stakes in healthcare, technology and infrastructure, but also introduces currency, governance and liquidity risks associated with a non?US listed vehicle. The stock’s performance will depend on the group’s ability to generate returns from its private?asset platform and manage its listed portfolio efficiently over the medium term.Marketscreener as of 07/05/2026

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.